Faster global financial news!
Eli Lilly
-
Eli Lilly and Company(LLY) Q3: EPS 7.48 USD (above forecast), Revenue 24.4B USD (above forecast)
Eli Lilly and Company(LLY) Q3 EPS: 7.48 USD; Forecast 5.68 USD Revenue: 24.4B USD; Forecast 22.58B USD Reporting period: 2026 Q3 (period ended 2026-09-30) Release date: 2026-10-29
-
Cramer: Tech insiders are surprisingly recommending Eli Lilly stock, anticipating its valuation could reach $2 trillion.
Cramer: Tech insiders are surprisingly recommending Eli Lilly stock, anticipating its valuation could reach $2 trillion.
-
Binance Exchange Adds JPMorgan Chase (JPMB), Eli Lilly (LLYB), Securitize Corp (SECZB) and StablecoinX Inc (USDEB) bStocks Trading Pairs on Binance Spot/Convert
Binance Exchange Adds JPMorgan Chase (JPMB), Eli Lilly (LLYB), Securitize Corp (SECZB) and StablecoinX Inc (USDEB) bStocks Trading Pairs on Binance Spot/Convert
-
Berenberg upgraded Eli Lilly to "buy" with a price target of $1,400, stating that its non-GLP-1 pipeline is undervalued.
Berenberg analyst Kerry Holford upgraded US pharmaceutical company Eli Lilly's rating from "Hold" to "Buy" this week, setting a price target of $1,400. Holford believes that while the market has fully
-
Dalio's Bridgewater and Wood's ARK Invest both held Eli Lilly and Nvidia in Q2
According to an analysis of their Q2 13F filings, Ray Dalio's Bridgewater Associates and Cathie Wood's ARK Invest both held shares in Eli Lilly (LLY) and Nvidia (NVDA). Bridgewater held 87,023 Eli Lil
-
24/7 Wall St. Analysts: Eli Lilly (LLY) Market Cap Exceeds $1 Trillion, Stock Expected to Rise Another 8.58% in Next 12 Months, Maintain "Buy" Rating
Analysts noted that Eli Lilly and Company's revenue reached $22.974 billion in Q2 2026, a 47.67% year-over-year increase, with earnings per share (EPS) of $8.38, exceeding market expectations by 27.27
-
Analysis: Novo Nordisk stock 'too cheap to ignore' after 66%+ drop from 2024 high, despite Eli Lilly GLP-1 competition
The Motley Fool analysis suggests that after Novo Nordisk's stock declined over 66% from its 2024 high, traditional valuation metrics like price-to-sales (4x vs 5-year average 8.6x) and price-to-earni
-
Billionaire Ken Griffin's Citadel fund nearly quadrupled its stake in Eli Lilly (LLY.US) in the second quarter, adding approximately 740,000 shares.
Ken Griffin's Citadel fund significantly increased its stake in pharmaceutical giant Eli Lilly in the second quarter of this year, making it one of the fund's top holdings. Eli Lilly is currently at t
-
Eli Lilly's Q2 revenue grew by 48%, and it plans to submit a BLA for its weight-loss drug Retatrutide in Q1 2027; Novo Nordisk, on the other hand, laid off 12,000 employees.
Eli Lilly reported a 48% increase in Q2 2026 revenue and raised its full-year guidance. Its weight-loss drugs, Mounjaro and Zepbound, generated a combined $14.9 billion in sales in Q2, capturing appro
-
Eli Lilly (LLY) stock rose 3.37% to $1223.04, narrowing the early lead of Novo Nordisk in the weight-loss drug market.
Eli Lilly's stock price has rebounded from its 50-day moving average and is currently above its 21-day and 10-day moving averages, demonstrating strong market performance. The company is challenging N
-
Yahoo Finance analysis points out that three healthcare stocks, Eli Lilly, Johnson & Johnson, and AbbVie, are worth watching in August due to their relatively poor market performance but strong fundamentals.
The analysis suggests that although the healthcare sector has underperformed the S&P 500 year-to-date, it has led all sectors over the past three months. Specifically, Eli Lilly's Q2 revenue increased
-
DeItaone reports that Eli Lilly (LLY) delivered strong Q2 results, exceeding expectations, and raised its full-year revenue guidance to $85.0-$87.0 billion, with adjusted EPS guidance of $35.50-$36.50.
Eli Lilly's Q2 adjusted EPS was $8.38, significantly exceeding the expected $6.01; revenue reached $22.97 billion, higher than the anticipated $20.73 billion. Of this, Mounjaro revenue was $9.94 billi
-
Weight Loss Drug Stocks Novo Nordisk, Eli Lilly Slump Below Key Levels
Weight Loss Drug Stocks Novo Nordisk, Eli Lilly Slump Below Key Levels
-
JPMorgan says one of the market’s ‘most durable growth’ sectors has been passed over for AI
JPMorgan states that one of the market’s “most durable growth” sectors has been overlooked by investors in favor of artificial intelligence (AI). The bank lists Eli Lilly, AbbVie, and Danaher Corporat
-
Eli Lilly and Company(LLY) Q3: EPS 7.48 USD (above forecast), Revenue 24.4B USD (above forecast)
Eli Lilly and Company(LLY) Q3 EPS: 7.48 USD; Forecast 5.68 USD Revenue: 24.4B USD; Forecast 22.58B USD Reporting period: 2026 Q3 (period ended 2026-09-30) Release date: 2026-10-29
-
Cramer: Tech insiders are surprisingly recommending Eli Lilly stock, anticipating its valuation could reach $2 trillion.
Cramer: Tech insiders are surprisingly recommending Eli Lilly stock, anticipating its valuation could reach $2 trillion.
-
Binance Exchange Adds JPMorgan Chase (JPMB), Eli Lilly (LLYB), Securitize Corp (SECZB) and StablecoinX Inc (USDEB) bStocks Trading Pairs on Binance Spot/Convert
Binance Exchange Adds JPMorgan Chase (JPMB), Eli Lilly (LLYB), Securitize Corp (SECZB) and StablecoinX Inc (USDEB) bStocks Trading Pairs on Binance Spot/Convert
-
Berenberg upgraded Eli Lilly to "buy" with a price target of $1,400, stating that its non-GLP-1 pipeline is undervalued.
Berenberg analyst Kerry Holford upgraded US pharmaceutical company Eli Lilly's rating from "Hold" to "Buy" this week, setting a price target of $1,400. Holford believes that while the market has fully
-
Dalio's Bridgewater and Wood's ARK Invest both held Eli Lilly and Nvidia in Q2
According to an analysis of their Q2 13F filings, Ray Dalio's Bridgewater Associates and Cathie Wood's ARK Invest both held shares in Eli Lilly (LLY) and Nvidia (NVDA). Bridgewater held 87,023 Eli Lil
-
24/7 Wall St. Analysts: Eli Lilly (LLY) Market Cap Exceeds $1 Trillion, Stock Expected to Rise Another 8.58% in Next 12 Months, Maintain "Buy" Rating
Analysts noted that Eli Lilly and Company's revenue reached $22.974 billion in Q2 2026, a 47.67% year-over-year increase, with earnings per share (EPS) of $8.38, exceeding market expectations by 27.27
-
Analysis: Novo Nordisk stock 'too cheap to ignore' after 66%+ drop from 2024 high, despite Eli Lilly GLP-1 competition
The Motley Fool analysis suggests that after Novo Nordisk's stock declined over 66% from its 2024 high, traditional valuation metrics like price-to-sales (4x vs 5-year average 8.6x) and price-to-earni
-
Billionaire Ken Griffin's Citadel fund nearly quadrupled its stake in Eli Lilly (LLY.US) in the second quarter, adding approximately 740,000 shares.
Ken Griffin's Citadel fund significantly increased its stake in pharmaceutical giant Eli Lilly in the second quarter of this year, making it one of the fund's top holdings. Eli Lilly is currently at t
-
Eli Lilly's Q2 revenue grew by 48%, and it plans to submit a BLA for its weight-loss drug Retatrutide in Q1 2027; Novo Nordisk, on the other hand, laid off 12,000 employees.
Eli Lilly reported a 48% increase in Q2 2026 revenue and raised its full-year guidance. Its weight-loss drugs, Mounjaro and Zepbound, generated a combined $14.9 billion in sales in Q2, capturing appro
-
Eli Lilly (LLY) stock rose 3.37% to $1223.04, narrowing the early lead of Novo Nordisk in the weight-loss drug market.
Eli Lilly's stock price has rebounded from its 50-day moving average and is currently above its 21-day and 10-day moving averages, demonstrating strong market performance. The company is challenging N
-
Yahoo Finance analysis points out that three healthcare stocks, Eli Lilly, Johnson & Johnson, and AbbVie, are worth watching in August due to their relatively poor market performance but strong fundamentals.
The analysis suggests that although the healthcare sector has underperformed the S&P 500 year-to-date, it has led all sectors over the past three months. Specifically, Eli Lilly's Q2 revenue increased
-
DeItaone reports that Eli Lilly (LLY) delivered strong Q2 results, exceeding expectations, and raised its full-year revenue guidance to $85.0-$87.0 billion, with adjusted EPS guidance of $35.50-$36.50.
Eli Lilly's Q2 adjusted EPS was $8.38, significantly exceeding the expected $6.01; revenue reached $22.97 billion, higher than the anticipated $20.73 billion. Of this, Mounjaro revenue was $9.94 billi
-
Weight Loss Drug Stocks Novo Nordisk, Eli Lilly Slump Below Key Levels
Weight Loss Drug Stocks Novo Nordisk, Eli Lilly Slump Below Key Levels
-
JPMorgan says one of the market’s ‘most durable growth’ sectors has been passed over for AI
JPMorgan states that one of the market’s “most durable growth” sectors has been overlooked by investors in favor of artificial intelligence (AI). The bank lists Eli Lilly, AbbVie, and Danaher Corporat
- No data
Eli Lilly
24H Trending
-
1
Samsung Electronics is down 4.44% from its previous close, now trading at ₩231,250.
-
2
Samsung Electronics fell 5.99% from its previous close, now trading at ₩227,500.
-
3
Nikkei Asia: Iranian separatists intensify attacks and seize territory in response to a potential full-scale US assault.
-
4
What is FLOW? An Analysis of the Flow Blockchain Ecosystem and Its Current Status
-
5
China's tech stocks lose luster as STAR 50 Index plunges over 40% from July peak, CATL falls 37% YTD amid AI profit doubts
-
6
LS Cable subsidiary Gaon Cable secures W120b ($90m) US AI data center cable deal
-
7
Report: Hedge Funds Exit Bitcoin ETF Arbitrage Trades, Sovereign Wealth Funds and Retail Investors Step In
-
8
Obama criticizes Trump's Iran war, citing US vulnerability and rising oil prices
-
9
Thailand's Kasikornbank taps AI to expand wealth management customer base
-
10
Iran's Islamic Revolutionary Guard Corps claims to have shot down a US-made MQ-1 drone near the Strait of Hormuz.
Markets Today
Recommended Reading
Hot Topics
Svmuu focuses on blockchain industry trends and cutting-edge cryptocurrency news, while also covering real-time market data and in-depth analysis of the Hong Kong, U.S., and foreign exchange markets. Here, you can not only access professional 24/7 news updates and accurate market data, but also utilize practical investment tools to help you capitalize on opportunities in both digital assets and traditional financial markets. Whether you are a blockchain enthusiast or an investor in Hong Kong, U.S., or foreign exchange markets, we provide efficient and timely information services to empower your investment decisions.
- User Agreement
- Privacy Policy
- Contact Us
- Business Partnerships
- Disclaimer
- Content Statement
- About Us
- Sitemap
Coming Soon!
